Abstract
We treated 13 children aged 0.2 years to 15.7 years (median 7.1 years) with flecainide acetate for refractory symptomatic supraventricular tachycardia. Six children had direct atrioventricular accessory pathways, of whom four had overt Wolff-Parkinson-White syndrome on the 12 lead electrocardiogram, while in the other two the accessory pathway was concealed. Three children had nodal atrioventricular re-entrant tachycardia, two had a re-entrant tachycardia, the exact mechanism of which was not known, one child had ectopic atrial tachycardia, and one had atrial flutter associated with an atrial septal defect. The remaining 12 children had structurally normal hearts. Flecainide (2 mg/kg intravenously) resulted in termination of the tachycardia in 11 of the 12 children treated during tachycardia. In 11 of the children successful prophylaxis was achieved with oral flecainide. Side effects occurred in two children during intravenous administration, but there were no side effects with oral treatment. This experience indicates that flecainide, which has not been used extensively in children, is an effective and safe antiarrhythmic agent, capable of terminating and controlling supraventricular tachycardia in children. Furthermore, flecainide may be successful where conventional agents fail.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anderson J. L., Stewart J. R., Perry B. A., Van Hamersveld D. D., Johnson T. A., Conard G. J., Chang S. F., Kvam D. C., Pitt B. Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med. 1981 Aug 27;305(9):473–477. doi: 10.1056/NEJM198108273050901. [DOI] [PubMed] [Google Scholar]
- Camm A. J., Hellestrand K. J., Nathan A. W., Bexton R. S. Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias. Drugs. 1985;29 (Suppl 4):7–13. doi: 10.2165/00003495-198500294-00003. [DOI] [PubMed] [Google Scholar]
- Gillette P. C. The mechanisms of supraventricular tachycardia in children. Circulation. 1976 Jul;54(1):133–139. doi: 10.1161/01.cir.54.1.133. [DOI] [PubMed] [Google Scholar]
- Hellestrand K. J., Bexton R. S., Nathan A. W., Spurrell R. A., Camm A. J. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J. 1982 Aug;48(2):140–148. doi: 10.1136/hrt.48.2.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nathan A. W., Hellestrand K. J., Bexton R. S., Banim S. O., Spurrell R. A., Camm A. J. Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. Am Heart J. 1984 Feb;107(2):222–228. doi: 10.1016/0002-8703(84)90368-5. [DOI] [PubMed] [Google Scholar]
- Ward D. E., Bennett D. H., Camm J. Mechanisms of junctional tachycardia showing ventricular pre-excitation. Br Heart J. 1984 Oct;52(4):369–376. doi: 10.1136/hrt.52.4.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ward D. E., Jones S., Shinebourne E. A. Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome. Am J Cardiol. 1986 Apr 1;57(10):787–790. doi: 10.1016/0002-9149(86)90614-4. [DOI] [PubMed] [Google Scholar]